title: Peripheral blood eosinophils from patients with allergic asthma contain increased intracellular eosinophil-derived neurotoxin.
abstract: BACKGROUND
  One mechanism of the eosinophil's contribution to airway inflammation in asthma is through release of cationic granule proteins to cause airway injury. Differences in either the intracellular concentration of granule proteins or the extent of activated degranulation between eosinophils from healthy patients and those with allergy and asthma could, therefore, relate to fundamental differences in this cell's function.
  
  
  OBJECTIVE
  To identify phenotypic differences in eosinophil-derived neurotoxin (EDN) content and release in eosinophils from healthy patients, those with allergy, and those with allergy and asthma.
  
  
  METHODS
  Peripheral blood eosinophils were isolated by negative anti-CD16 selection. Total intracellular and cytokine-activated release of EDN protein was measured by radioimmunoassay. EDN mRNA was assessed by real-time PCR.
  
  
  RESULTS
  Eosinophils from patients with asthma contained significantly more EDN per cell than comparable cells from healthy patients, those with allergy but without asthma, or those with asthma treated with inhaled corticosteroids, but they had concentrations similar to airway eosinophils isolated from bronchoalveolar lavage fluid 48 hours after segmental bronchoprovocation with allergen. Furthermore, this increased granule protein was reflected in more EDN degranulation by IL-5- or GM-CSF-activated eosinophils when calculated as nanograms of protein secreted but not when calculated as a percentage of total EDN release. Levels of EDN mRNA were similar in all subject groups.
  
  
  CONCLUSIONS
  These data suggest that peripheral blood eosinophils from subjects with untreated asthma have increased inflammatory capacity, as reflected by greater intracellular concentrations of EDN.
authors.affiliation: Allergy and Immunology, Department of Medicine, University of Wisconsin, Madison, WI 53792, USA. jxs@medicine.wisc.edu
authors.forename: Julie B
authors.initials: JB
authors.lastname: Sedgwick
authors.forename: Rose F
authors.initials: RF
authors.lastname: Vrtis
authors.forename: Kristyn J
authors.initials: KJ
authors.lastname: Jansen
authors.forename: Hirohito
authors.initials: H
authors.lastname: Kita
authors.forename: Kathleen
authors.initials: K
authors.lastname: Bartemes
authors.forename: William W
authors.initials: WW
authors.lastname: Busse
mesh_terms: D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000276:immunology / Q000503:physiopathology*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D015550:Cell Degranulation; D047208:Eosinophil-Derived Neurotoxin; D004804:Eosinophils / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000503:physiopathology*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012260:Ribonucleases / Q000097:blood* / Q000235:genetics
chemical_list: D012333:RNA, Messenger; D047208:Eosinophil-Derived Neurotoxin; D012260:Ribonucleases